Chemoprevention Considerations in Patients with Hereditary Colorectal Cancer Syndromes
- Resource Type
- Authors
- Karen Hurley; Carol A. Burke; Mohamad Mouchli; Mahnur Haider; Carole Macaron; Gautam Mankaney
- Source
- Gastrointestinal Endoscopy Clinics of North America. 32:131-146
- Subject
- Oncology
Secondary prevention
medicine.medical_specialty
education.field_of_study
Colorectal cancer
business.industry
Population
Gastroenterology
Cancer
medicine.disease
Chemoprevention
Colorectal Neoplasms, Hereditary Nonpolyposis
Lynch syndrome
Familial adenomatous polyposis
Adenomatous Polyposis Coli
Neoplastic Syndromes, Hereditary
Internal medicine
medicine
Humans
In patient
Colorectal Neoplasms
business
education
- Language
- ISSN
- 1052-5157
Secondary prevention of colorectal neoplasia with chemoprevention is long-studied area of research and clinical use in patients with the 2 most common hereditary colorectal cancer syndromes including Lynch syndrome and familial adenomatous polyposis. No medication is currently approved for use for the prevention of colorectal polyps or cancer in either the general population or individuals with the hereditary colorectal cancer syndromes. Emerging data in animal models and limited data in humans suggest vaccines may be the next breakthrough for neoplasia prevention in patients with hereditary colorectal cancer. Clinicians must acknowledge chemoprevention is an adjunct and does not supplant endoscopic surveillance.